Vice President of Emerging Genome Technology
Christopher Mason, PhD, is Tempus’ Vice President of Emerging Genome Technology. Dr. Mason has been a pioneer in next-generation sequencing (NGS) diagnostics, multi-omic approaches to modeling disease, and new biochemical and genomic methods. At Tempus, Dr. Mason is developing and advising on the cutting-edge technologies needed for NGS profiling, host responses to COVID-19, and computational methods for linking clinical metadata to multi-omic trajectories in patients. Dr. Mason joined Tempus from Weill Cornell Medicine, where he is an Associate Professor of Genomics, Physiology, and Biophysics, as well as the Director of the WorldQuant Initiative for Quantitative Prediction. There, he specialized in developing new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and physiology.